Trial Profile
Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Orismilast (Primary) ; Midazolam
- Indications Atopic dermatitis; Psoriasis
- Focus Pharmacokinetics
- Sponsors LEO Pharma
- 09 Aug 2017 Planned End Date changed from 1 Aug 2017 to 1 Oct 2017.
- 09 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Oct 2017.
- 02 Jun 2017 Status changed from not yet recruiting to recruiting.